Add-on TOXCLEAN for recurrent C. difficile diarrhea
Part of Digestive system, Infections clinical trials.
This trial tests an add-on treatment called TOXCLEAN for people with repeat C. difficile diarrhea. It aims to see if adding TOXCLEAN to standard antibiotics helps more than antibiotics alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have had recurrent C. difficile diarrhea (a new episode that started 2 to 8 weeks after a previous one cleared up).
- You have already taken at least one full course of antibiotics (like vancomycin, metronidazole, or fidaxomicin) for this infection.
- You do not have other bowel diseases (like Crohn's, ulcerative colitis) or a history of bowel surgery.
- You are not taking blood thinners (like warfarin or apixaban).
- You are not pregnant or breastfeeding, and you do not have a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the supplement alanyl-glutamine, given along with standard treatment, can improve outcomes for adults being treated for C. difficile infection (a cause of diarrhea). It may help the body recover better after antibiotics that usually treat C. difficile.
This trial studies whether fecal microbiota transplantation (a procedure that transfers healthy stool bacteria) can change a person’s gut bacteria after repeated C. difficile infection. It may help reduce recurring infections by restoring a healthier balance of gut microbes.
This study tests a new live bacteria product (EXL01) given with vancomycin to prevent C. diff from coming back. It is for people who have already had C. diff two or more times and are at high risk of another infection.
This study looks at levels of C. diff toxins in stool after standard antibiotic treatment. It aims to understand how toxins change during recovery, which may help improve future treatments for C. diff infections.
This trial studies how Clostridioides difficile (C. diff) affects healthy people by intentionally giving a controlled dose. The goal is to understand the infection better and help develop future treatments or vaccines.
This trial tests a new treatment called CMTS0929 for people with C. diff infection. It aims to see if the treatment can help clear the infection and improve symptoms.
Hear when a new Clostridium; Difficile, As Cause of Disease Classified Elsewhere trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.